slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 226,471-226,500
Pages 10,126
Rows per page 30
Component
226,471-226,500 of 303,780
02
Immix Biopharma | Investor Presentation Deck | 60 slidesImmix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
07
Uses a hub-and-spoke diagram to illustrate the central problem of neurotoxicity and its four primary negative consequences.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
13
Includes a cartoon liver character at the bottom.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
15
The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
17
The slide uses a multi-panel line chart with timeline bars to contrast clinical outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
20
Includes a disclaimer about cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
21
The slide uses a table structure to contrast patient segments and includes a bar chart representation for patient growth.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
24
Uses a visual icon-grid to represent market expansion.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market SizingLoop · Golden Circle1 hit
25
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
26
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
27
The slide uses a standard pharmaceutical pipeline table format, categorizing assets by clinical vs. preclinical status and highlighting specific clinical trial results and regulatory designations.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
29
The slide uses a visual wave/area chart metaphor to represent market segments and their respective valuations.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
31
The slide uses a complex table structure to compare patient demographics and clinical outcomes across three cohorts.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
32
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
33
The slide uses a side-by-side comparison of two disease indications, each with its own clinical data points and relevant market benchmarks.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
62
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient therapy thesis.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
63
The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
64
The slide uses a bar-grouped chart format to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit